CYP2C18 GWAS Links CYP2C19 to Plavix Response; Randomized-Controlled Trial, PGx Consortium to Come Premium Following the GWAS, researchers plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for clopidogrel. Breaking News New Products Posted to GenomeWeb: Vizgen, Bruker, Standard BioTools, BioMérieux, IDT, More BioSkryb Genomics, Tecan Partner for High-Throughput Single-Cell Sample Prep HudsonAlpha Launches Pilot Project to Study Genetics, Lifestyle of Alzheimer's Disease In Brief This Week: 23andMe, Syncell, BioSkryb, Ultima Genomics, Galatea Bio, Genetic Alliance, More Interpace Diagnostics to Cease PancraGen Testing After Losing CMS Reimbursement
